| Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations M Dankner, AAN Rose, S Rajkumar, PM Siegel, IR Watson Oncogene 37 (24), 3183-3199, 2018 | 351 | 2018 |
| Osteoactivin promotes breast cancer metastasis to bone AAN Rose, F Pepin, C Russo, JE Abou Khalil, M Hallett, PM Siegel Molecular Cancer Research 5 (10), 1001-1014, 2007 | 211 | 2007 |
| Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer AAN Rose, AA Grosset, Z Dong, C Russo, PA MacDonald, NR Bertos, ... Clinical cancer research 16 (7), 2147-2156, 2010 | 210 | 2010 |
| ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties AAN Rose, MG Annis, Z Dong, F Pepin, M Hallett, M Park, PM Siegel PloS one 5 (8), e12093, 2010 | 204 | 2010 |
| GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis AB Dydensborg, AAN Rose, BJ Wilson, D Grote, M Paquet, V Giguere, ... Oncogene 28 (29), 2634-2642, 2009 | 170 | 2009 |
| Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer G Maric, AAN Rose, MG Annis, PM Siegel OncoTargets and therapy, 839-852, 2013 | 149 | 2013 |
| Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer J Bendell, M Saleh, AAN Rose, PM Siegel, L Hart, S Sirpal, S Jones, ... Journal of Clinical Oncology 32 (32), 3619-3625, 2014 | 118 | 2014 |
| Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases S Tabariès, V Ouellet, BE Hsu, MG Annis, AAN Rose, L Meunier, ... Breast cancer research 17 (1), 1-18, 2015 | 114 | 2015 |
| Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis AAN Rose, C Elser, M Ennis, PJ Goodwin Breast cancer research and treatment 141, 331-339, 2013 | 109 | 2013 |
| Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cells M Demers, AAN Rose, AA Grosset, K Biron-Pain, L Gaboury, PM Siegel, ... The American journal of pathology 176 (6), 3023-3031, 2010 | 92 | 2010 |
| Emerging therapeutic targets in breast cancer bone metastasis AAN Rose, PM Siegel Future oncology 6 (1), 55-74, 2010 | 92 | 2010 |
| Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer AAN Rose, M Biondini, R Curiel, PM Siegel Pharmacology & therapeutics 179, 127-141, 2017 | 77 | 2017 |
| GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin α5β1 for efficient breast cancer metastasis G Maric, MG Annis, Z Dong, AAN Rose, S Ng, D Perkins, PA MacDonald, ... Oncogene 34 (43), 5494-5504, 2015 | 72 | 2015 |
| Breast cancer-derived factors facilitate osteolytic bone metastasis AAN Rose, PM Siegel Bulletin du cancer 93 (9), 931-943, 2006 | 72 | 2006 |
| Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanomas M Dankner, M Lajoie, D Moldoveanu, TT Nguyen, P Savage, S Rajkumar, ... Clinical Cancer Research 24 (24), 6483-6494, 2018 | 59 | 2018 |
| Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition A Rogiers, IP Da Silva, C Tentori, CA Tondini, JM Grimes, MH Trager, ... Journal for ImmunoTherapy of Cancer 9 (1), 2021 | 55 | 2021 |
| MAPK pathway inhibitors sensitize BRAF-mutant melanoma to an antibody-drug conjugate targeting GPNMB AAN Rose, MG Annis, DT Frederick, M Biondini, Z Dong, L Kwong, L Chin, ... Clinical Cancer Research 22 (24), 6088-6098, 2016 | 49 | 2016 |
| Exon-level transcriptome profiling in murine breast cancer reveals splicing changes specific to tumors with different metastatic abilities A Bemmo, C Dias, AAN Rose, C Russo, P Siegel, J Majewski PloS one 5 (8), e11981, 2010 | 36 | 2010 |
| Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+ anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy AAN Rose, SM Armstrong, D Hogg, MO Butler, SD Saibil, DP Arteaga, ... Journal for immunotherapy of cancer 9 (1), 2021 | 31 | 2021 |
| Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma. AAN Rose Drugs of today (Barcelona, Spain: 1998) 55 (4), 247-264, 2019 | 31 | 2019 |
Matthew AnnisMcGill University, Research AssociateVerified email at mcgill.ca
